ArticleTherapeutic innovation & regulatory science2026
Interpreting Non-Inferiority Across Effect Scales: A Bayesian Perspective with Clinical Translation.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study examines how the choice of non-inferiority margins affects the clinical interpretation of interventional studies using the Santos et al. trial comparing high-flow nasal cannula (HFNC) with non-invasive ventilation (NIV) as a case example. We also demonstrate how Bayesian reanalysis improves interpretability by expressing non-inferiority margins on absolute and relative scales, quantifying posterior probabilities of non-inferiority and benefit, and translating these margins into patient-centred measures such as the Number Needed to Harm (NNH).
designSecondary Bayesian reanalysis of a previously published randomised controlled trial.
settingMulticentre paediatric intensive care units participating in the original Santos et al. study. PATIENTS: Infants with acute bronchiolitis were randomised to receive either HFNC or NIV.
interventionsRespiratory support via HFNC or NIV.
main outcome measuresThe primary endpoint was intubation, with the intubation rate reported as a descriptive summary statistic. We re-expressed the original non-inferiority margin on the Absolute Risk Reduction (ARR) and Odds Ratio (OR) scales, estimated Bayesian probabilities of non-inferiority and benefit, and derived patient-centred metrics such as the NNH.
resultsThe original analysis concluded non-inferiority using a fixed absolute margin. Our Bayesian reanalysis showed that this margin could correspond to a substantial relative tolerance when baseline risks are low; specifically, the 0.15 non-inferiority ARR margin might imply a doubling of the odds of intubation. When interpreted from a patient-centered perspective, this margin corresponds to an NNH of approximately 6.7. In other words, for every seven infants treated with HFNC instead of NIV, one additional child might require intubation who would not have needed it under standard care.
conclusionsNon-inferiority margins are typically derived through a combination of statistical evidence and clinical judgment. However, their interpretation may vary depending on the effect scale used, and this may not always be transparent in reporting. For this reason, integrating Bayesian methods and framing multiple noninferiority definitions improves the interpretability of trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.